Theravance Bioph Stock Price, News & Analysis

Theravance Biopharma (TBPH) reported Q1 2021 total revenue of $14.3 million, a decrease of $5.6 million YOY, attributed mainly to collaboration revenue from Viatris. While YUPELRI's market share grew to 19%, overall net sales faced a slight decline. R&D expenses increased to $67.6 million, leading to an operating loss of $83.9 million. The company anticipates full-year R&D expenses between $195 million and $225 million. Notable upcoming clinical milestones include results for nezulcitinib and izencitinib trials expected in Q2 and Q3 2021.

Theravance Biopharma (NASDAQ: TBPH) will announce its first quarter 2021 financial results on May 4, 2021, after market close. A conference call will follow at 5:00 p.m. ET. The company focuses on organ-selective medicines and aims to improve patient lives. Its notable product includes YUPELRI® for COPD. This update will provide critical insights into financial performance and business developments crucial for investors.

Theravance Biopharma (NASDAQ: TBPH) will participate in a pre-recorded Fireside Chat at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021. Interested investors can access the webcast through the 'Investors' section of Theravance's website, specifically under 'Events and Presentations.' A replay of the event will be available for at least 30 days. Theravance Biopharma focuses on developing organ-selective medicines, particularly in the areas of inflammation and immunology, aiming to improve patient outcomes.

Theravance Biopharma (TBPH) announced its financial results for Q4 and full year 2020, highlighting 159% year-over-year sales growth for YUPELRI, now capturing 18.6% of the nebulized COPD market. Despite this growth, total revenue for Q4 decreased by $10.8 million to $18.7 million, with a full year revenue of $71.9 million. Operating loss increased to $76.5 million in Q4. The company is optimistic about ongoing clinical trials, particularly for TD-0903 in COVID-19 patients, and expects significant milestones in 2021, including data releases for ongoing studies. Cash reserves stood at $292.9 million.

Theravance Biopharma (NASDAQ: TBPH) announced its participation in key investor events. Management will engage in a Fireside Chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 24 at 12:00 p.m. ET. Additionally, Richard A. Graham will join the GI/Microbiome Panel at the Cowen 41st Annual Cowen Conference on March 2 at 11:10 a.m. ET. Interested investors can access the webcast via the "Investors" section on Theravance's website, where replays will be available for 30 days.

Theravance Biopharma (NASDAQ: TBPH) will announce its fourth quarter and full year 2020 financial results on February 23, 2021, after market close. A conference call and webcast are scheduled for 5:00 p.m. ET. The company focuses on organ-selective medicines, targeting inflammation and immunology. Notably, it has developed YUPELRI®, an inhalation solution for COPD. The announcement may impact investors keen on financial performance metrics and future growth prospects.

Theravance Biopharma (NASDAQ: TBPH) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 2:00 p.m. ET. The presentation will focus on the company's commitment to developing organ-selective medicines aimed at treating serious illnesses, particularly in inflammation and immunology. Investors can access the webcast on the company's website and the replay will be available for 30 days. Theravance's research includes the approved YUPELRI® inhalation solution for COPD, showcasing its focus on patient-centered drug development.

Theravance Biopharma (NASDAQ: TBPH) will webcast its presentation at the 3rd Annual Evercore ISI HEALTHCONx Conference on December 1, 2020, at 2:40 p.m. ET. The webcast can be accessed via the Investors section of their website www.theravance.com. Replay will be available for 30 days. The company specializes in organ-selective medicines, focusing on inflammation and immunology, with an aim to improve patient lives. Their notable product includes YUPELRI®, an FDA-approved treatment for chronic obstructive pulmonary disease.

Theravance Biopharma (NASDAQ: TBPH) reported Q3 2020 total revenue of $18.3 million, driven by a significant rise in YUPELRI's sales, which contributed approximately $13.0 million to the revenue. However, the company reported an operating loss of $76.6 million due to increased R&D and SG&A expenses, totaling $67.4 million and $27.5 million respectively. Cash reserves stood at $358.3 million. Despite market challenges from COVID-19, YUPELRI gained market share and brand profitability. The company also anticipates key clinical trial results in Q3 2021 for its pipeline products.